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Introductory Remarks and Statement of Purpose:
Estrogens and estrogen mimetic compounds have long been
known to be potent growth promoters. It is also well established
that within the cells of estrogen target organs there are
proteins which act as specific receptors and as such bind
estrogen against a concentration gradient (1). Additionally,
these proteins are capable of carrying the estrogenic molecule
across the nuclear membrane in an as yet not fully understood,
thermally activated mechanism. Once inside the nucleus , the
estrogenic molecule (that is estrogenic in binding ability) will
then either enhance or diminish transcription, translocation, and
subsequently protein growth.
As growth promoters, the estrogens have also been found to
enhance the growth of some forms of tumor tissue, which mimic
classic estrogen target organs. As such the need for effective
antiestrogens becomes clear in that minimizing the amount of
estrogen available (or the degree to which it can be utilized) it
is possible to reduce or even negate the growth of hormone-
responsive tumors.
The exact nature of what constitutes an estrogenic versus
antiestrogenic compound remains mechanistically uncertain and
J.
subsequently has relied largely on empirical data and related
rationalizations. The comparison series found in Figure 1
illustrates some of the fundamental characteristics considered to
be of importance regarding the efficacy of any particular
antagonist in relation to several agonists. For example, the
nonpolar aromatic side chain, as well as the aminoether 6ide
chain are thought to be of key importance in the effective
antagonism of the estrogenic response.
Furthermore, there is an activated estrogen-receptor complex
known to be crucial to the induction of protein synthesis which
seems a likely avenue through which effective estrogen antagonism
may be pursued. This plan of attack is more viable in view of the
so called promiscuous nature of the estrogen receptor, which is
to say that it is susceptible to binding with compounds other
than
its'
intended. Subsequently, strong, irreversible binding of
the receptor to a biologically inactive compound is considered of









Estrogens are the hormones responsible, in part, for
producing and controlling the primary and secondary sexual
characteristics in females. The natural mammalian estrogens:
estradiol, estrone, and estriol (Figure 1) are structurally
fairly simple compounds but produce profound biochemical effects.
Among the more significant discoveries in cellular biology in the
past twenty years or so, was that proteins within the cells of
higher organisms can selectively bind such steroids in specific
target tissue and retain them against a concentration gradient.
These eukaryotic cells have a highly developed capacity for
enzyme induction and positive regulation of the synthesis of
specific proteins in response to these sex hormones. The first
observation of the selective retention of labeled estradiol in
estrogen target tissue by Jenson and Jacobson initiated
intensified research aimed at elucidating the subcellular
mechanism of estrogen action (2). Thus far it has been demon
strated that binding of the hormone-receptor complex to DNA
(chromatin) causes increased rates of RNA synthesis
(transcription) and ultimately the synthesis of characteristic
proteins. Hence it is the
hormone-
receptor complex itself which
acts as the inducing agent, probably by binding to a specific
4.
locus in the appropriate chromosome. As a result much of the more
recent research has involved the search for these receptor
proteins, via isolation and analysis.
Such research typically follows a pattern of: 1. study of
the uptake and retention of a labeled hormone 2. identification of
the hormone presumed to be the active form 3. detection and
isolation of a specific protein that binds an active steroid but
not an inactive steroid with a high affinity and exists in larger
amounts in target cells than in insensitive cells, and 4. the
demonstration that antagonists can interfere with receptor
binding of an active steroid (1).
The isolation, in a pure form, of the receptor proteins has
generally faced two major difficulties: what appears to be an
inherent instability of the receptor and the tendency of these
proteins toward aggregation. In addition the quantities of
receptor proteins are low in target tissue (they being
"inducible") and it is therefore necessary to purify extensively
to achieve pure samples. Such purification typically involves
some form of affinity chromatography.
Through these search and isolate techniques concentrated
efforts are being directed toward the discovery of the molecular
mechanism whereby a steroid-receptor complex may participate in
the regulation of gene expression in the target cells.
5.
Mechanism of Action of Estrogens:
Estrogens are capable of crossing cell membranes passively
due to their lipophilicity, entering the cytoplasm, and there
bind with a specific cytoplasmic receptor protein to form a
cytoplasmic estrogen-receptor complex (ERc). This receptor is
present only in the cells of estrogen target tissue and is
invariably absent in cells which are not responsive to estrogen
(2). After the cytoplasmic estrogen-receptor complexation there
occurs a temperature dependent activation step which produces
noticeable changes in the physicochemical
characteristics-
of the
receptor. This transformation or activation process is poorly
understood but appears to occur via a two step mechanism. At
least three different mechanisms have been proposed to account
for this process; Notides proposes a pseudo-dimerization
involving addition of other proteins to the receptor, Puca has
proposed a calcium ion activated proteolysis, and Rochefort
presents a simple conformational change (2).
The resulting complex, termed the nuclear estrogen-receptor
complex (ERn), then translocates into the nucleus wherein the
hormone exerts its influence on gene activity. In addition there
appears to be an alteration of the nuclei, also temperature
dependent, which facilitates receptor binding (1). Following
(p.
translocation the cytoplasmic receptor concentration decreases
and receptor concentration in the nucleus increases
proportionately. In addition this activated form of the receptor
binds to DNA (chromatin) at least fifteen times more tightly than
does the initial form, potentially enhancing localization of
the receptor in the nucleus (2).
This, then leads to increased RNA synthesis and eventually to
an increased synthesis of cytoplasmic proteins and hence a
rapid regeneration of newly formed receptors. This continuous
source of newly formed receptor is necessary for maximum
stimulation of target cells by estrogen. Finally DNA synthesis
and hyperplasia begin approximately twentyfour hours after
initial exposure to estrogen.
Although it is known that translocation and nuclear binding
are necessities in eliciting a cellular response to estrogen,
specific information regarding the means by which the complex
modulates some biosynthetic events is lacking. Particularly,
attempts to determine the nuclear site of receptor interaction
have been somewhat unsuccessful.
Pharmacodynamics/Therapeutic Considerations :
In view of the fact that estrogen is known to be a potent
growth promoter the ramifications must be considered then, as a
7.
result of reports stating that some forms of cancerous tumor
tissue behave in many ways like a classic estrogen target
organ. As such they are capable of concentrating estrogen and
utilizing it toward enhanced growth, propagation, and metastasis
of the carcinoma. In such a case it is therefore desirable to
minimize the amount of estrogen available and hence reduce or
perhaps negate the growth of the cancer.
As might be expected then, among the more significant
advantages arising from increased understanding of steroid
hormone action is the successful application of the new
concepts toward therapy for hormone-responsive tumors. In
addition, such advances have been beneficial in providing
information regarding the selection of patients likely to benefit
from hormone therapy.
Since estrogen is known to be bound to intracellular
receptors in target organs it was reasoned that the hormone may
undergo the same physicochemical changes upon entry into the
endocrine responsive tumor cell (3). Subsequently the
estrogen-
receptor activated complex will again be a crucial stage in the
process leading to enhanced protein synthesis. This consideration
is particularly noteworthy in view of the promiscuous nature of
the estrogen receptor. Moreso than other biological receptors,
the estrogen receptor has the capability to bind a wide variety
of structural types within a general structural type, yet at the
same time be highly selective in distinguishing small
stereochemical and structural changes (2).
The indications are, then, that the estrogenic response is
particularly susceptible to control via agonists or antagonists.
As a result the mechanism of antagonism has been as actively
sought as the actions of estrogens themselves in the belief that
knowledge of the former will clarify the latter. Additionally,
such information will be useful in and of itself as regards the
clinical or therapeutic applications of antiestrogens.
Antiestrogens are considered any of a group of compounds
which block at least in part the action of estrogen on target
tissue. Such antagonists should be designed with the intention of
having exceptionally high receptor affinity and little or no
biological activity. In the past investigators have relied on
semi-empirical approaches comparing structure and end point
activity as predictive tools. Such an approach can catch the
investigator in a confusing and often redundant cycle. (Figure
2.)
In related studies of receptor binding of androgens it
appears that the receptor binds simultaneously at multiple
sites/sides, as if enveloping the androgenic steroid (1).
Similarly, it appears that steric as opposed to electronic
factors are of greater significance regarding a biological
response (1,4).
Potential Sites/Methods of Antagonism:
From Figure 3. it 6eems there are a number of possible
methods whereby effective antagonism of estrogen on the target
cell may be obtained. We might look first at blocking the actual
entrance of estrogen into the cell, or perhaps impair the
formation of the estrogen receptor complex. However, some
antiestrogens inhibit cell growth more so than those grown in
estrogen free serum, hence this cannot be the sole method of
inhibition. Secondly, weaken the chromatin-complex
formation/interaction. This is accomplished through weak or
impeded estrogens which result in premature dissociation of the
antiestrogen-receptor complex, presumably because they cannot
sustain the prolonged activation/translocation of the nuclear
receptor. This is not considered likely to be a major mechanism
of antagonism. Antagonism by altering transformation.
Antiestrogens apparently allow transformation to occur,but alter
it likely through subtle physicochemical differences which cause
the antiestrogen receptor complexes to interact differently with
chromatin, thereby ineffectually triggering biochemical
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subcellular distribution of estrogen receptors. Estrogen-receptor
complexes and antiestrogen-receptor complexes also differ in
length of nuclear residency and biosynthetic events stimulated
therein. Estrogen-receptor complexes are cleared from the nucleus
rapidly and cytoplasmic receptor synthesis is stimulated. The
antiestrogen-receptor complexes, however, show a long nuclear
residency and tie up cytoplasmic receptors as well as depleting
their resynthesis, and when cytoplasmic receptor levels are low
the cell is unresponsive to estrogenic stimulation.
The recent interest and subsequent availability of the
nonsteroidal antiestrogens and their metabolites has facilitated
comparative studies of the antiestrogen versus estrogen receptor
interactions. From such studies it is apparent that agonist and
antagonist bind to the same or closely related sites, the
aminoether side chain of the antagonist is necessary for both
binding and antagonist activity and substitutions on the chain
markedly affect the affinity for the antiestrogen binding site.
The rates of association are similar whereas the rates of
dissociation vary among the antagonists relative to estrogen.
A structural comparison of nonsteroidal antagonists versus
agonists generally exhibit the following differences; 1. the
agonist is a bisarylethylene whereas the antagonist is a




substitution but the antagonist has only one hydroxyl group, 3.
the agonist has no basic, or polar, side chain yet the antagonist
does (2).
The picture, however, is still too vague and complex to form
definite conclusions regarding the most important factors in
estrogen antagonism. Furthermore there is no definitive proof
that any one particular molecular event that differs between an
agonist and an antagonist is responsible for inhibition of
receptor mediated estrogen action and many of the proposed
mechanisms are either still too controversial or have been
discarded. As a result there is an unfortunate tendency to speak
of antiestrogens in a broad context rather than individual
compounds or closely related analogs. It is not known, for
example, whether or not the same functional groups are
responsible for both antiestrogenic and antitumor activity. Such
knowledge is imperative for rational selection and synthesis of
compounds for further clinical development and for a greater
understanding of estrogenic/hormonal mechanisms (5).
H.
DISCUSSION
It has been reported(6) that, in vivo, tamoxifen is
transformed to hydroxytamoxifen which has a much higher binding
affinity for the estrogen receptor and appears to be a more
biologically active metabolite, as regards antiestrogen activity.
In a recent article, Sutherland and Murphy(5) compile reports
which together suggest that metabolic activation of nonsteroidal
antiestrogens to monohydroxylated derivatives in a position
corresponding to the three position of estradiol probably
enhances but is not required for antiestrogen activity.
The synthesis of bromohydroxytamoxifen has been reported by
Robertson and Katzenellenbogen(7) and the authors allude to a
facile E-Z interconversion process. The E isomer of tamoxifen
has no clinical use and in fact is reported to be a potent
agonist (5). It is the Z isomer then, which is shown to exhibit
antiestrogenic behaviour.
It is the purpose of this part of the study to produce
bromohydroxytamoxifen, separate the E and Z isomers and 6tudy, if
possible, the kinetics of the E to Z interconversion. In addition
it is hoped that separation of these isomers can allow
1 13
determination of the H and C spectra in order to
provide clear spectral evidence for differentiation between Z and
15.
E geometric isomers in the triarylethylene series. Such
assignments have been tentative at best, in the past.
In attempts to avoid this geometric isomerization, similar
nonsteroidal antiestrogens have been proposed which contain the
more rigid napthalene structure. Such a compound is our
nafoxidine analog. A major portion of this project then, is the
total synthesis of this compound from 6-methoxytetralone and
p-bromophenol. Although biological studies of the compound itself
(or analogs thereof) are to be found in the literature(8) there
appear to be no reports of the actual synthesis. This aspect of
the project then represents not merely a novel synthesis but the
first reported synthesis of nafoxidine.
Hydroxytamoxifen
The synthesis of 4-hydroxytamoxifen followed that of
Robertson and Katzenellenbogen(8) which is outlined in Figure 4.
The acid chloride of p-bromophenylacetic acid is formed
using PCI. in refluxing benzene. To the acid chloride is then
added a large excess of anisole, followed by a solution of
stannic chloride in benzene, added dropwise. The resulting deep
red solution gave a red oil upon work up, which crystallized
readily from methanol giving white crystals m.p. 139-141C.
















by forming the carbanion with sodium hydride in THF, followed by
nucleophilic attack with ethyl iodide via an S 2 mechanism.
The mixture was stirred one hour and quenched with 5% HCl. Work
up and purification by column chromatography gave a light yellow
oil in 78% yield.
The aryl methyl ether is then deprotected to the phenol via
ethane thiolate. The thiolate is prepared by adding ethane thiol
to sodium hydride in DMF. It was found to be crucial to maintain
the temperature of the reaction mixture at or below 5 C.
during this addition, the consequences of which being
significantly reduced yields. The aryl methyl ether is then added
as a solution in DMF in one portion and refluxed. The reaction is
quenched with 10% HCl and work up gave a viscous red oil. Column
chromatography made possible the separation of starting materials
and product. The phenol was obtained as a yellow oil in 89.4%
yield, and recrystallization from methylene chloride/hexane gave
off white crystals, mp 119-121C.
The phenol is now converted to the amino ether compound via
a Williamson ether synthesis. This is carried out by formation of
the phenolate in sodium ethoxide followed by the addition of
2-dimethylaminoethylchloride-hydrochloride in ethanol followed by
refluxing for two days. The reaction was quenched with water and
work up including purification by column chromatography gave the
IS.
product as a viscous yellow oil in 49.4% yield, with IR spectrum
free of 0-H stretch.
The THP ether of p-bromophenol is formed by adding neat DHP
to the p-bromophenol containing catalytic p-toluenesulfonyl
chloride. Work up and purification gave white crystals readily
from aqueous 90% ethanol in 72% yield.
The protected p-bromophenol is then employed in a Grignard
reaction with the butanone. The Mg complex of the protected
p-bromophenol is formed in THF using standard Grignard reaction
methods. A solution of the butanone in THF is then added slowly
to the Grignard reagent resulting in mild exothermia. The mixture
was refluxed for two hours, stirred overnight and quenched by
drowning it into cold saturated ammonium chloride. Work up and
purification by column chromatography gave a brown oily solid
which was found to be a mixture of the E and Z isomers. Although
chromatography on silica gel gave moderate separation of E (oil)
and Z (solid) isomer, the E to Z inter conversion was so rapid
that isolation of pure E was not possible, and prevented kinetic
studies of this isomerization as well as an in depth NMR analysis
of both isomers.
Nafoxidine Analog Synthesis (initial)
A Grignard reaction analogous to the final step of the










hydroxytamoxifen synthesis is carried out with 6-methoxytetralone
and the THP ether of p-bromophenol.
As in the analogous case the reaction wa6 quenched with
cold, saturated ammonium chloride and worked up appropriately
giving a light yellow oil. Attempts at crystallizing this yellow
oil were unsuccessful. Additionally column chromatography
attempts were unsuccessful in that the only systems which
appeared to give good separation by TLC were those in which the
oil is insoluble, and the neat oil was too viscous too penetrate
the silica gel bed. The IR data indicated by absence of carbonyl
stretch at 1690 cm that the product or intermediates had
been formed. At this stage it was difficult to determine whether
a moderate 0-H stretch in the IR was the result of incomplete
dehydration of the Grignard intermediate or partial cleavage of
the THP protecting group. Similarly, NMR data was ambiguous since
the THP made interpretation difficult, particularly at higher
field. As a result the neat oil was converted directly to the
epoxide.
The epoxide was formed in methylene chloride by reaction
with m-chloroperbenzoic acid. The mixture of the crude oil, the
peracid, and methylene chloride
was stirred overnight which gave
m-chlorobenzoic acid precipitating out of solution. The mixture
was chilled, filtered and the filtrate was worked up giving a
;i.
dark amber oil. Crystallization attempts were again unsuccessful
as were attempts at column chromatography. The IR data indicated
that the reaction had taken place by the appearance of the
epoxide C-0 stretch, in addition what appeared to be the product
spot on the TLC plate had a reduced Rf in comparison to the
starting material, as expected.
This final reaction of this series was carried out in THF at
dry ice/ isopropanol temperatures. The epoxide as a crude oil was
taken up in THF and a 1.9M solution of phenyl lithium in hexane
was added dropwise, keeping the reaction temperature below -45 C.
Maintaining reaction temperature at -60 C. the reaction
mixture was stirred for two hours and warmed to room temperature
with stirring overnight. The reaction was quenched with cold 10%
HCl. Due to increasingly complicated identification/purification
problems the final work up and isolation were never successfully
completed. Alternatively a new, more viable synthetic sequence
was devised.
Nafoxidine Analog Synthesis (revised)
Through the course of the preceding work it was noticed that
the p-bromophenol was initially protected with an ether linkage
only to be deprotected
back to the phenol from which another
ether was made. Thus it became suspect that the preceding
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sequence involved a superfluous step or two and that these steps
could be avoided with a more direct approach. This revised
sequence accomplishes just that according to the following
rationale. Since the purpose of the protecting group is to avoid
the presence of a potential proton donating species (i.e. -OH,
-NH ) and thus enhance the potential for a successful Grignard
reaction it is clear that the new protecting group is equally
effective as it contains only a tertiary amine and subsequently
no threat of proton donation.
Therefore, the above Williamson ether synthesis was
attempted and successfully carried out in sodium ethoxide. After
refluxing for two days, appropriate work up, and purification,
the above ether was obtained as a nearly colorless oil in 73%
yield.
As anticipated, this aryl amino ether did indeed convert to
the Grignard reagent and wa6 somewhat readily converted to the
olefin folowing dehydration of the intermediate alcohol. The
initiation of the Grignard reagent was somewhat delayed, however,
this may be attributable to environmental factors (high humidity)
and/or incomplete drying/purification of the halide.
Additionally, dehydration of the intermediate alcohol was found
to require conditions somewhat more vigorous than one might
expect in view of the extensive conjugation present in the
molecule. Complete dehydration was obtained only after ten hours
in refluxing 10% HCl (as indicated by IR). Purification was
achieved by vacuum distillation, collecting the product at
205-
215 C. at 0.6mm Hg. The resulting light brown oil was
resistant to standard crystallization techniques, however it
tended to cryatallize on standing from the neat oil. The
distillation gave very clean product (by NMR) in 33% yield.
The epoxide is formed as previously outlined, by combining
the olefin and the m-chloroperbenzoic acid in methylene chloride,
stirring overnight, filtering off the reduced peracid, and
working up appropriately. As in previous cases, however, the
epoxide was somewhat difficult to purify by standard techniques
efficiently, but efficient washings, carbon treatment, and
removal of solvent gave an off white bubbly glass in 95% yield.
The proton NMR was poorly resolved, however, the vinyllic triplet
was noticeably absent and the IR showed classic epoxide C-O-C
stretching.
The phenyl group is now added at the three position of the
1,2-dihydronapthalene skeleton by opening the epoxide with phenyl
lithium. The electrophilic opening of the epoxide by the
organolithium reagent leaves the three position susceptible to
nucleophilic attack by the phenyl carbanion. The oxygen- lithium
complex is then hydrolyzed and the resulting intermediate alcohol
25.
is dehydrated with refluxing 10% HCl giving the
substituted
olefin which is the targeted nafoxidine analog. Characterization
by proton NMR was clear and unambiguous.
Furthermore, the methyl iodide salt of the amine was
prepared in an attempt to obtain in crystalline form a derivative
of the product. Crystallization of the derivative was
unsuccessful, however, strong evidence for it having been formed
is found in the proton NMR spectrum in which the methyl amine
protons are shifted almost 1.5 ppm downfield (deshielding effect
of the positive charge now on the nitrogen) and the integration
as compared to the methoxyl peak changed from 2:1 to 3:1 as
anticipated.
Utilization of the information gained in the nafoxidine
synthesis allows some potential modifications of the
4-Hydroxy tamoxifen synthesis. Such modifications are outlined in
Figure 7, the viability and applicability of these modifications






















A 200 ml. reaction flask was charged with 20.25g. (0.093
moles) of bromophenylacetic acid and 40 mis. of benzene. To this
stirring suspension was added 20.25g. (0.096 moles) of phosphorus
pentachloride, portionwise to avoid foaming. The brown mixture is
stirred until a solution is obtained, then refluxed for one-half
hour. The solution was then cooled to
0
C. and 44.5 mis.
(0.411 moles) of anisole i6 added in one portion. Stannic
chloride (26mls., 57. 8g. , 0.222moles ) in 45mls. of benzene is
then added dropwise, resulting in a deep red solution.
The reaction mixture was then stirred for seven hours and
quenched with 300 mis. of 3N HCl with ice/water cooling. The
mixture was extracted with ethyl acetate (3x100 mis.) and the
combined extracts were washed with water (2x100 mis.). Drying
over magnesium sulfate and removal of solvent in vacuo gave a red
oil which crystallized readily from methanol to give white
crystals (20. 5g. , 72.3%) with m. p.
139-141
C. ; I.R.(CC14)
1690 (C=0) ; 1NMR (CDC13) ( ,ppm) 3.83 (s,3, 0CH-),
4.12 (s,2,-CH2), 6.85 (d,2, J=10Hz.,ArH ortho to -0CH3),
7.05 (d,2,J-10Hz.,ArH ortho to alkyl), 7.38 (d,2,J-10Hz. ,ArH
ortho to -Br), 7.90 (d,2, J=12Hz. ,ArH ortho to carbonyl).
2-(4-Bromophenyl)-l-(4-methoxyphenyl)-l-butanone (2) ;
A 1.0 liter reaction flask is charged with a suspension of
2.0g. (0.083 moles) of sodium hydride in 300mls. of dry
(*=
Aldrich Gold Label) THF*. The supension is cooled to 0 C. and
20. Og. (0.06 moles) of (1) in 400mls. THF* was added dropwise
over 30 minutes. The green mixture was allowed to warm slowly to
room temperature and stirred for two hours. The solution was
again cooled to
0
C. and ethyl iodide (15.5mls., 30g. , 0.192
moles) was added. The mixture was stirred at 0 C. for one
hour and then quenched by the slow addition of 150mls. of 5% HCl.
The mixture was poured into 800ml s. of water and extracted with
ether (4x75mls.). The ether extracts were washed with 150 mis.
saturated sodium chloride solution, dried (magnesium sulfate) and
roto-
vapped to an oil.
The oil was purified via column chromatography (silica gel),
eluting with 25% ethyl acetate in hexane. Product is the first
yellow band eluting from column, (17.15g., 0.0515moles, 78.5%),
IR (CC14)
1690cm"1
(C=0). XH NMR (CDC13) ( ,ppm)
0.87 (t,3,J-6Hz.,-CH2CH3), 1.68-2.25 (m,2,-CH2CH3),
3.85 (s,3, -0CH3), 4.33 (t, l,J-6Hz. ,=CH-CH2CH3), 6.85
(d,2,ArH ortho to -0CH3), 7.15 (d,2,ArH ortho to alkyl), 7.38
(d,2,ArH ortho to -Br), 7.90 (d,2,ArH ortho to C=0).
3D.
2-(4-Bromophenyl)-l-(4-hydroxyphenyl)-l-butanone (3) s;
A 1.0 liter reaction flask was charged with 330mls. of dry
DMF*, to which 4.25g. (0.177 moles) of sodium hydride is added.
The suspension is cooled to
0
C. and ethanethiol (12.67g.,
15.0ml8., 0.204 moles) is added dropwise so as to maintain the
temperature below
5
C. The mixture is then stirred for ten
minutes and 17. Og. (0.051 moles) of (2) in 95mls DMF* is added in
one portion. The brown mixture is heated slowly to 140 C. for
two hours.
The mixture was then poured into llOOmls. of 10% HCl and
extracted with ether until a clear extract is obtained. The
combined ether extracts are then washed with 10% HCl ( 2x200mls.
), saturated NaCl solution, dried (mag nesium sulfate) and
roto-vapped to a viscous red oil. Treatment of the oil with
decolorizing carbon removed some color and column chromatography
(silica gel) eluting with 5% methanol in methylene chloride
brought off starting material (2) very near the solvent front and
product (3) following as a yellow band. Removal of solvent gave a
viscous yellow oil; (89.4%), IR (neat oil) 3675 and 3460
(0-H), and 1680 (C=0), XH NMR (CDCl3) (
,ppm) 0.90 (t,3,J=HHz.,-CH2CH3), 1.7-2.4 (m,2,-CH2CH3) ,
4.45 (t,l,J=HHz.,-CHCH2CH3), 6.45 (s,l,-0H), 6.88
(d,2,ArH ortho to -OH) ,7.10 (d,2,ArH ortho to alkyl), 7.42
31.
(d,2,ArH ortho to -Br), 7.95 (d,2,ArH ortho to carbonyl).
2-dimethylaminoethyl) phenyl ether of (3) (4);
A 500ml. reaction flask was charged with 90mls. of absolute
ethanol to which is added sodium metal (1.30g., 0.0565 moles) and
stirred until all sodium is dissolved. To this is added 8.45g.
(28.06 mmoles) of (3) in 90mls. of absolute ethanol. A solution
of 2-dimethylaminoethylchloride hydrochloride (4.38g.,
30.40mmoles) in 90mls of absolute ethanol was added in one
portion to the phenolate solution, resulting in the immediate
precipitation of NaCl. The mixture was refluxed for 18 hours,
cooled to room temperature and poured into 1.2 liters of water.
The product was extracted from the aqueous solution with ether
(4xl00ml6.) and the combined ether extracts were washed with 5%
NaOH, and saturated NaCl solution. Drying (magnesium sulfate) and
removal of solvent in vacuo gave the product as a light brown
oil. Purification by column chromatography (silica gel) eluting
with benzene/TEA (9:1) gave three observable bands, product is
the middle band, which upon removal of solvent gave a viscous
yellow oil (5.40g., 49.4% ), IR (CC14) 1695 (C=0),
1610 (Ar C-C str.), 1195 (C-O-C), H NMR
(CDC13) ( ,ppm) 0.70 (t,3,J7.6Hz.,-CH2CH3),
, 2
a.
1.90-2.25 (m,2, -CH2CH3) .38 (s,6, -N(CH3)2),
2.78 (t,2,J=6.6Hz.,_OCH2CH2"N),4.12 (t,2, J=6.0Hz. ,
-OCH2CH2N=, coalesced with t,l, CHCH2CH3),
6.70-7.60 (m,8, ArH).
4-Bromophenyl tetrahydropyranyl ether (5);
The reaction flask is charged with p-bromophenol (32. 6g.,
0.189moles) and cooled to
0
C. The dihydropyran (63. 7g.,
0.75 moles) is then added dropwise, containing catalytic (10mg.)
p-toluenesulfonyl chloride. The addition results in a reddish
brown solution which dissipates to a yellow solution after
stirring overnight.
TLC (hexane eluent) indicates completion and 80mls. of ether
i6 added and the mixture is washed with 40mls. of 5% NaOH. Drying
(magnesium sulfate) and removal of solvent in vacuo gives a
viscous yellow oil. Purification by column chromatography (silica
gel) eluting with hexane gave a turbid, almost colorless oil
which crystallized readily from aqueous ethanol (90%) to a white






Hydroxytamoxifen Bromide (E,Z mixture) (6);
A dry 300ml . reaction flask was charged with magnesium
(1.55g., 86.34 mmoles) , heated with a mantle, to dry the system,
and purged with nitrogen. After cooling to room temperature
55.
20mls. of dry THF* is added. With stirring a solution of (5) in
25ml s. dry THF* is added, initially as a five ml. portion then
dropwise after initiation (denoted by slight discoloration and
exothermia). Initiation occurred readily.
When all of (5) had been added the mixture was stirred with
mild heat for 45 minutes. A solution of (4) (5.60g., 14.4 mmoles)
in 50ml s. dry THF* was then added via addition funnel. The
addition was mildly exothermic, resulting in a light brown
solution. The solution was refluxed for two hours, cooled to room
temperature and stirred overnight.
The solution was then poured into 100ml s. saturated NH.C1
with ice/ water cooling. The Mg salts did not crystallize out so
the mixture was washed with water OxlOOmls.), and saturated
NaCl. Drying (magnesium sulfate) and removal of solvent in vacuo
resulted in a dark brown viscous oil.
The oil was taken up in 225ml s. of methanol and 3. 75ml s of
HCl (cone.) was added, with cooling, immediately yielding a much
darker solution. This was stirred overnight, solvent removed and
the dark oil was slurried with 600 mis. water, neutralized to pH
7 with 3M NaOH, and extracted with ether (5xl00mls. ). Carbon
treatment, drying (magnesium sulfate) and removal of solvent in
vacuo gave a brown oil.
Purification by column chromatography (silica gel) eluting
ft
with acetone/ methylene chloride (1:1) gave a light brown oil
solid. Crystallization attempts were unsuccessful. IR (neat oil)
3400 (OH); XH NMR (acetone-d, ), ( ,ppm) 0.92
o
(t,3, J=5.0Hz., -CH2CH3), 2.13 and 2.17 (s,6,-NCH322) ,
2.45 - 2.78 (m,4, -0CH2CH2N=, and CH2CH3), 3.90
-
4.08 (m,2, -0CH2CH2N=), and 6.70 - 7.33 (m,12, ArH).
Nafoxidine Analog, (Initial Synthesis):
THP ether of 4-(4'-Hydroxyphenyl)-7-methoxy-l,2-dihydronapthalene
(8c);
A 1.0 liter reaction flask was charged with 15.19g. of Mg,
in lOOmls. dry THF*. With stirring, (123.Og. , 0.48 moles) of the
protected phenol (5) as a solution in 375ml s dry
THF* was added,
initially a 20ml. aliqout, and following initiation, dropwise.
When all of (5) had been added, the mixture was refluxed for
twenty minutes, and allowed to cool to room temperature. The
6-methoxytetralone (22. 0g., 0.125 moles) as a solution in 250mls.
THF* was then added dropwise, resulting in a dark green mixture
which was refluxed for 1.5 hours and stirred overnight.
With cooling the reaction mixture was poured slowly into
400mls. of saturated ammonium chloride solution, giving a white
precipitate, which
redissolved into solution. The layers were
separated and the organic layer was washed well with water to
remove Mg salts.
35.
Attempts at crystallizing the light yellow oil
proved
unsuccessful. Similarly, purification by column chromatography
proved awkward and impractical as the oil was sufficiently
viscous as to be incapable of penetrating the silica gel bed.
Subsequently, based on IR data (absence of =C=0 at 1690 cm )
the product was converted directly to the epoxide from the crude
oil.
THP ether of 4-(4'-Hydroxyphenyl)-7-methoxy-l,2-dihydronapthalene
(9a);
A 1.0 liter reaction flask was purged with nitrogen and
charged with (8c) (31.55g., 0.125 moles) as a crude oil, 500mls.
of methylene chloride and m-chloroperbenzoic acid (47.42g., 0.275
moles). The light yellow solution was stirred at room temperature
overnight.
The reduced peracid precipitated out as m-chlorobenzoic acid
and was removed via filtration. The filtrate is then washed,
first with saturated Kl (3xl00mls.), sodium thiosulfate
(2xl00mls.), and saturated sodium bicarbonate (lxlOOmls.).
Significant emulsion problems resulted during these washings. The
methylene chloride solution was dried (magnesium sulfate) and
removal of solvent in vacuo gave a dark amber oil which proved
difficult to crystallize. IR Data supported anticipated
occurrence of reaction (appearance of epoxide C-0 stretch), in
0(0.
addition TLC showed a decreased R- of product relative to
starting material. As a result the oil was then converted
directly to the -3-phenyl-l,2-dihydronapthalene compound.
4- (4
*
-Hydroxyphenyl )-7-methoxy- 1 , 2-dihydronapthalene ( 10b ) ;
A 1.0 liter reaction flask was purged with nitrogen and
charged with the epoxide as a crude oil in 300mls. THF*. The
solution was cooled in a dry ice/ isopropanol bath to -50 C.
and 70mls. (10.29g., 0.130 moles) of a 1.9M solution of phenyl
lithium was added dropwise so as to keep solution temperature
below -45 C. The solution was stirred for two hours at -60
C. and allowed to warm slowly to room temperature and stirred
overnight.
With ice/water cooling the reaction mixture was cooled below
15 C. and the reaction was quenched via the addition of
350ml s. of 10% HCl and stirred overnight.
Final work up and isolation incomplete.
Nafoxidene Analog (Revised Synthesis):
4-Bromophenyl-2-dimethylaminoethyl ether (7);
To 20mls. of absolute ethanol is added 0.46g. (0.020 moles)
of freshly cut sodium metal. When the sodium is completely
dissolved, 1.46g. (0.008 moles) of p-bromophenol in 25mls. of
absolute ethanol is added in one portion. This clear solution was
37.
warmed to 50 C. for 1 hour, cooled to room temperature and
the 2-dimethylaminoethyl chloride hydrochloride (1.32g. ,0.009
moles) in 30mls. absolute ethanol i6 added in one portion. This
addition gives immediate precipitation of NaCl. This mixture was
refluxed for two days, quenched by the addition of water and
stripped to a slurry to remove ethanol. More water was then added
and the product was extracted from the aqueous layer with ether
(2x30mls.). The ether layer was then washed with 10% NaOH
(2x25mls.) to remove remaining phenol, then with saturated
ammonium chloride, and finally with water. Drying (magnesium
sulfate), and removal of solvent in vacuo gave a nearly colorless
oil (1.5g., 73%); XH NMR (CDC13) ( ,ppm) 2.27
(s,6,-NCH322),2.7 (t,2, J-8Hz., -CH2CH2N=),
3.97 (t,2,J=6Hz.,-0CH2CH2N=), 6.70 (d,2, ArH para





)-7-methoxy- 1 , 2-dihydronapthalene (8b ) ;
A 1.0 liter reaction flask was purged with nitrogen and
charged with 5.6g. (0.230 moles) of Mg and 60mls. of dry THF*.
With stirring 34.Og. (0.139 moles) of (7) in 40mls.
THF* is
added, initially as an 8ml. portion, and then dropwise in
anticipation of initiation. Initiation was considerably delayed
but did eventually take place. The mixture was then refluxed for
1.5 hours and allowed to cool slightly. The 6-methoxytetralone
(10. 6g., 0.060 moles) in 50mls. THF* was then added dropwiBe and
upon the completion of which the mixture was refluxed for 3
hours.
With ice/water cooling the mixture was poured into 400mls.
of saturated ammonium chloride solution and the product was
extracted with ether ( 4x100 mis.). The ether layer was washed
with water until colorless washings were obtained, dried over
magnesium sulfate, carbon treatedand roto-vapped to an oil. IR
indicated very limited dehydration of alcohol, so the oil was
taken back up in ether and refluxed in 10% HCl overnight, giving
complete dehydration according to IR. H NMR at this stage,
however, was still very messy and inconclusive. Attempts at
purification by column chromatography (silica gel and alumina)
were unsuccessful. Finally a vacuum distillation gave very nearly
pure product by NMR, coming over as the fourth fraction at 205
-
215
C. at 0.6mm. Hg. Although the light brown oil tended to
crystallize from the neat oil attempts at recrystallizing from a
variety of solvent systems
proved unsuccessful. Yield: 6.4g. or
33.4%. XH NMR (CDCl3) ( ppm) 2.30 (s,6,-NCH3a2) ,
2.75 (m,6, coalesced multiplets, -CHCH2CH2, -CH2CH2N0,
3.75 (s,3,-0CH3), 4.08 (t,2,-OCH2CH2N=), 5.90




-Hydroxyphenyl )-7-methoxy-3 1 , 2-dihydronapthalene
(9b);
A 250ml. reaction flask was purged with nitrogen and charged
with (8b) (l.Og., 3.09 mmoles) as a solution in 30mls. of
methylene chloride. To this is then added a solution of
m-chloroperbenzoic acid (1.06g., 6.18 mmoles) in 40mls. of
methylene chloride. No precipitation of m-chlorobenzoic acid
resulted, so an additional 0.25g. of the peracid was added,
stirred overnight, cooled the mixture, and filtered off any
precipitate. The filtrate was washed with saturated Kl
(2x30mls.), 10% sodium thiosulfate (2x30mls.), water (lx40mls.)
and saturated NaCl (2x40mls.). Drying (magnesium sulfate) and
removal of solvent in vacuo gave an off-white bubbly glass.
Carbon treatment and tritrating with methylene chloride/hexane
gave a whiter glass (0.95g., 95%). h NMR (CDC13)
disappearance of vinyllic triplet, IR epoxide C-O-C at 1310 cm. ,




-Hydroxyphenyl )-7-methoxy-3-phenyl-l , 2-dihydronapthalene
(10c)
*J0.
A 100ml. reaction flask was purged with nitrogen and charged
with 0.95g. of the epoxide in 30mls. THF*. The solution was then
cooled to C. with a dry ice/isopropanol bath. A 1.9M
solution (1.6mls., 0.252g., 3.0 mmoles) of phenyl lithium was
added dropwise at such a rate as to maintain the temperature
below -50 C. After addition is complete the mixture is
stirred for two hours at C, allowed to warm slowly to
room temperature and stirred overnight.
The reaction is quenched with 10% HCl and refluxed for two
hours. IR data indicated incomplete dehydration so reaction was
refluxed overnight. The mixture was worked up by neutralizing
with 10% NaOH and extracting the product with ether (3x25mls.).
The ether layer was washed with 10% NaOH, saturated NaCl and then
dried (magnesium sulfate). Removal of solvent in vacuo gave a
dark brown oil showing complete dehydration by IR.
Purification by column chromatography (alumina), eluting
with absolute ethanol gave a dark brown oil which appeared
cleaner by TLC, but still showed two spots. Further purification
by column chromatography (alumina) now using methanol seemed to
give better separation by TLC, however, separation off the column
was only very slightly better, still resulting in two spots.
Attempts at recrystallization were unsuccessful. H NMR
(CDC13) ( ,ppm) 1.84 (t,2, allylic methylene), 2.30
il.
(d,6,J=0.3Hz.,-N(CH3)2), 2.69 (m,4,benzylic
methylene, -CH2N), 3.72 (s,3,-OCH3), 4.0 (m,>2,-OCH2
and impurity), 6.63-7.45 (m, 12,ArH).
Methyl iodide salt of (10c) (11);
To a solution of lOOmg. of (10c) in 4 mis of ethanol is
added 1.5 mis of methyl iodide with cooling. The mixture is
allowed to warm to room temperature and stirred for two hours.
Attempts at crystallization from methanol or ethanol were
unsuccessful. The resulting oil was treated with carbon in
methanol and upon removal of solvent gave an off-white glass. H
NMR (CDC13) ( ,ppm) 3.48 (s,9,-N+-CH323), 3.70
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